COVID-19 and risk of pulmonary fibrosis: the importance of planning ahead

Phua J Weng L Ling L , et al. Intensive care management of coronavirus disease 2019 (COVID-19): Challenges and recommendations. Lancet Respir Med. Epub ahead of print 6 April 2020. DOI:10.1016/S2213-2600(20)30161-2.

Cheung OY Chan JWM Ng CK , et al. The spectrum of pathological changes in severe acute respiratory syndrome (SARS). Histopathology 2004; 45: 119–124.

Hui DS Wong KT Ko FW , et al. The 1-year impact of severe acute respiratory syndrome on pulmonary function, exercise capacity, and quality of life in a cohort of survivors. Chest 2005; 128: 2247–2261.

Ngai JC Ko FW Ng SS , et al. The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. Respirology 2010; 15: 543–550.

Zhang P Li J Liu H , et al. Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: A 15-year follow-up from a prospective cohort study. Bone Res 2020; 8: 8.

Chang YC Yu CJ Chang SC , et al. Pulmonary sequelae in convalescent patients after severe acute respiratory syndrome: evaluation with thin-section CT. Radiology 2005; 236: 1067–1075.

Wu X Dong D Ma D. Thin-section computed tomography manifestations during convalescence and long-term follow-up of patients with severe acute respiratory syndrome (SARS). Med Sci. Monit 2016; 22: 2793–2799.

Zhang H Zhou P Wei Y , et al. Histothologic changes and SARS-CoV-2 immunostaining in the lung of a patient with COVID-19. Ann Intern Med. Epub ahead of print 12 March 2020. DOI:10.7326/M20-0533.

Cabrera-Benitez NE Laffey JG Parotto M , et al. Mechanical ventilation-associated lung fibrosis in acute respiratory distress syndrome: A significant contributor to poor outcome. Anesthesiology 2014; 121: 189–198.

Zhao X Nicholls JM Chen YG , et al. Severe acute respiratory syndrome-associated coronavirus nucleocapsid protein interacts with Smad3 and modulates transforming growth factor-beta signaling. J Biol Chem 2008; 283: 3272–3280.

Tilocca B, Soggiu A, Sanguinetti M, et al. Comparative computational analysis of SARS-CoV-2 nucleocapsid protein epitopes in taxonomically related coronaviruses. Microb Infect. Epub ahead of print 14 April 2020. DOI:10.1016/j.micinf.2020.04.002.

Zuo W Zhao X Chen YG. SARS coronavirus and lung fibrosis. In: Lal S (ed.) Molecular biology of the SARS-coronavirus. Berlin and Heidelberg: Springer, 2010, pp.247–258.

Barison A Aimo A Castiglione V , et al. Cardiovascular disease and COVID-19: les liaisons dangereuses. Eur J Prev Cardiol. 2020; 27: 1017–1025.

Villar J Confalonieri M Pastores S , et al. Rationale for prolonged corticosteroid treatment in the acute respiratory distress syndrome caused by coronavirus disease 2019. Crit Care Explor 2020; 2: e0111.

Brojakowska A Narula J Shimony R , et al. Clinical implications of SARS-Cov2 interaction with renin angiotensin system. J Am Coll Cardiol. Epub ahead of print 15 April 2020. DOI: 10.1016/j.jacc.2020.04.028.

Collins BF Raghu G. Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis. Eur Respir Rev 2019; 28: 190022.